{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:45:32Z","timestamp":1792673132204,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tracli.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:28:59Z","timestamp":1784388539000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups"],"prefix":"10.1016","volume":"33","author":[{"given":"Jay","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Jimenez Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudette Gail","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-0823","authenticated-orcid":false,"given":"Abdulaziz F.","family":"Al Mana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2026.07.008_bib0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tracli.2026.07.008_bib0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.tracli.2026.07.008_bib0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.tracli.2026.07.008_bib0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3892\/ol.2023.13924","article-title":"Cytopenia after CAR-T cell therapy: analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"26","author":"Qiu","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tracli.2026.07.008_bib0135","doi-asserted-by":"crossref","first-page":"997589","DOI":"10.3389\/fimmu.2022.997589","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.tracli.2026.07.008_bib0140","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","article-title":"Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors","volume":"54","author":"Xia","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.tracli.2026.07.008_bib0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/trf.17793","article-title":"Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy","volume":"64","author":"Perera","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.07.008_bib0150","doi-asserted-by":"crossref","first-page":"215920","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.tracli.2026.07.008_bib0155","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.07.008_bib0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.46989\/001c.126463","article-title":"Prolonged cytopenia with CAR-T cell therapy and management recommendations","volume":"7","author":"Dahunsi","year":"2025","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.tracli.2026.07.008_bib0165","doi-asserted-by":"crossref","first-page":"e006406","DOI":"10.1136\/jitc-2022-006406","article-title":"Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party","volume":"11","author":"Penack","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tracli.2026.07.008_bib0170","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.tracli.2026.07.008_bib0175","series-title":"Regression analysis of count data","author":"Cameron","year":"2013"},{"key":"10.1016\/j.tracli.2026.07.008_bib0180","series-title":"Nonparametric statistical inference","author":"Gibbons","year":"2020"},{"key":"10.1016\/j.tracli.2026.07.008_bib0185","series-title":"Negative binomial regression","author":"Hilbe","year":"2011"},{"key":"10.1016\/j.tracli.2026.07.008_bib0190","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.tracli.2026.07.008_bib0195","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jtct.2025.01.264","article-title":"Incidence and severity of cytopenias secondary to CD19-targeted CAR-T cell therapy: a systematic review and meta-analysis","volume":"31","author":"Shahzad","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.tracli.2026.07.008_bib0200","doi-asserted-by":"crossref","first-page":"IJH02","DOI":"10.2217\/ijh-2017-0023","article-title":"Management of older adults with acute lymphoblastic leukemia: challenges and current approaches","volume":"7","author":"Sawalha","year":"2018","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.tracli.2026.07.008_bib0205","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2026.07.008_bib0210","first-page":"335","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma","volume":"389","author":"Martin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.07.008_bib0215","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.07.008_bib0220","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:11:10Z","timestamp":1792671070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782026001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1246782026001199"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2026.07.008","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 francophone de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}